Merck's discount wins NICE nod for Keytruda; FDA flags user-error worries with Purdue's new painkiller;

> Merck & Co.'s ($MRK) new cancer immunotherapy Keytruda won backing from the U.K.'s cost-effectiveness watchdogs after offering an unspecified discount. Report

> FDA staff reviewers flagged likely errors in administering Purdue Pharma's new fast-acting oxycodone painkiller, saying taking the drug with food can interfere with its effectiveness. Report

> Canadian regulators cleared Recordati's rare disease drug Carbaglu for marketing, as a treatment for hyperammonemia. Report

> Two leading U.S. physicians' organizations say proposed megamergers in the health insurance business will be anti-competitive. Report

And Finally... U.K. life sciences groups, including pharma companies, urged the government not to cut research funding, citing the economic benefits of R&D work. Report

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.